drugset / Trial / NCT01453348

Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine

NCT01453348 ↗

Phase 3 Completed 252 enrolled Novartis Vaccines GlaxoSmithKline · collab
RandomizedParallel-groupOpen-labelPrevention

Summary

This study compares the safety and immunogenicity profile of combined hepatitis A/B vaccine given alone or concomitantly with MenACWY-CRM to healthy adults.

Timeline

Start
2011-10
Primary completion
2012-01
Completion
2012-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Combined inactivated hepatitis A & recombinant hepatitis B Vaccine — Intramuscular
Comparator Inactivated hepatitis A vaccine Vaccine — Intramuscular
Comparator MenACWY-CRM Vaccine — Intramuscular
Comparator recombinant hepatitis B vaccine Vaccine — Intramuscular